ClinicalTrials.gg
CompletedNCT00259090Updated Aug 16, 2012Results posted

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

A Phase 2 interventional study of Fulvestrant and Anastrazole in Breast Cancer, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to female participants. Per ClinicalTrials.gov, last updated 2012-08-16.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
39th of 94
120 · median 71
Started
2004
with 9 others
Phase 2
59 of 95
8 open now
Registered
17th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 39th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 59 in phase 2, and was the 17th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women.
  • confirmation of primary breast cancer.
  • Oestrogen receptor positive tumour.
  • Fit for surgery within one month.
  • Written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with any anti-hormonal therapy for breast cancer.
  • Previous radiotherapy to the primary tumour.
  • Previous chemotherapy for the primary tumour.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    1

    Anastrozole Monotherapy

    Drug: Anastrazole

  • Experimental
    2

    Fulvestrant Monotherapy

    Drug: Fulvestrant

  • Experimental
    3

    Anastrozole + Fulvestrant

    Drug: Fulvestrant · Drug: Anastrazole

Interventions

  • 500 mg intramuscular injection

    Also known as: Faslodex, ZD9238

  • oral tablet

    Also known as: Arimidex, ZD1033

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.

    For each sample, the ER H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)\]. Range 0-300. The greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100

    Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)

  2. Percentage Change From Baseline to Time of Surgery in Progesterone Receptor (PgR) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the PgR H-score.

    For each sample, the PgR H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent+/-) + (1 x percent+) + (2 x percent++) + (3 x percent+++)\]. Range 0-300. The greater the change from baseline (randomization in PgR H-score, the greater the blockage of PgR expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100

    Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)

  3. Percentage Change From Baseline to Time of Surgery in Ki67 Labelling Index: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the Ki67 Labelling Index.

    For each sample, the Ki67 labelling index is calculated as the percentage of cells stained positive for Ki67. Range 0-100. The greater the change from baseline (randomization) in Ki67 labelling index, the greater the blockage of Ki67 expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100

    Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)

07

Results

Posted Aug 16, 2012

Participant flow

Postmenopausal women with oestrogen receptor positive breast cancer, awaiting curative-intent surgery were recruited to 4 medical centres within the UK.

Participant flow — Overall Study
MilestoneFulvestrantFulvestrant + AnastrozoleAnastrozole
Started353137
Completed353137
Not completed000

Outcome measures

PrimaryPercentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.

For each sample, the ER H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)\]. Range 0-300. The greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100

Time frame:
Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.
Percentage change from baselineFulvestrantFulvestrant + AnastrozoleAnastrozole
Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.-37 ± 4-38 ± 5-7 ± 6
PrimaryPercentage Change From Baseline to Time of Surgery in Progesterone Receptor (PgR) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the PgR H-score.

For each sample, the PgR H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent+/-) + (1 x percent+) + (2 x percent++) + (3 x percent+++)\]. Range 0-300. The greater the change from baseline (randomization in PgR H-score, the greater the blockage of PgR expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100

Time frame:
Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline to Time of Surgery in Progesterone Receptor (PgR) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the PgR H-score.
Percentage change from baselineFulvestrantFulvestrant + AnastrozoleAnastrozole
Percentage Change From Baseline to Time of Surgery in Progesterone Receptor (PgR) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the PgR H-score.-31 ± 8-38 ± 12-38 ± 7
PrimaryPercentage Change From Baseline to Time of Surgery in Ki67 Labelling Index: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the Ki67 Labelling Index.

For each sample, the Ki67 labelling index is calculated as the percentage of cells stained positive for Ki67. Range 0-100. The greater the change from baseline (randomization) in Ki67 labelling index, the greater the blockage of Ki67 expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100

Time frame:
Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline to Time of Surgery in Ki67 Labelling Index: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the Ki67 Labelling Index.
Percentage change from baselineFulvestrantFulvestrant + AnastrozoleAnastrozole
Percentage Change From Baseline to Time of Surgery in Ki67 Labelling Index: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the Ki67 Labelling Index.-62 ± 4-68 ± 6-75 ± 4

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant—0/40 (0%)18/40 (45%)
Fulvestrant + Anastrozole—3/40 (7.5%)13/40 (32.5%)
Anastrozole—2/40 (5%)17/40 (42.5%)
Most frequent serious events
Most frequent serious events
EventFulvestrantFulvestrant + AnastrozoleAnastrozole
PancytopeniaBlood and lymphatic system disorders0/400/401/40
Atrial FibrillationCardiac disorders0/401/400/40
Unevaluable EventGeneral disorders0/401/400/40
Subcutaneous AbscessInfections and infestations0/400/401/40
Procedural ComplicationInjury, poisoning and procedural complications0/401/400/40
Most frequent other events
Most frequent other events
EventFulvestrantFulvestrant + AnastrozoleAnastrozole
Hot FlushVascular disorders7/403/408/40
Pain In ExtremityMusculoskeletal and connective tissue disorders0/404/402/40
HeadacheNervous system disorders3/404/403/40
ConstipationGastrointestinal disorders3/401/402/40
DyspepsiaGastrointestinal disorders3/400/401/40
NauseaGastrointestinal disorders0/403/402/40
Injection Site RashGeneral disorders3/400/400/40
Unevaluable EventGeneral disorders3/400/403/40
Injection Site PainGeneral disorders2/401/403/40
RashSkin and subcutaneous tissue disorders1/403/400/40

Baseline characteristics

Age, Customized
Age, Customized(Participants)FulvestrantFulvestrant + AnastrozoleAnastrozoleTotal
50 - 59 years7 ± 8.513 ± 10.510 ± 8.730 ± 9.0
60 - 69 years1371434
70 - 79 years136928
80 - 89 years2327
Not available0224
Sex: Female, Male
Sex: Female, Male(Participants)FulvestrantFulvestrant + AnastrozoleAnastrozoleTotal
Female353137103
Male0000
08

Study locations

1 site
  • Research Site
    Nottingham, United Kingdom
09

References and documents

Publications

  • Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO, Channon E, Hyman-Taylor P, Nicholson RI, Gee JM. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. Breast Cancer Res. 2013 Mar 5;15(2):R18. doi: 10.1186/bcr3393. PubMed 23497452 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2005
First posted
Nov 29, 2005
Start
Apr 2004
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Aug 16, 2012
Last update
Aug 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00259090
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 29, 2005
Start date
Apr 2004
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Aug 16, 2012
Last update
Aug 16, 2012

Study contacts

AstraZeneca Faslodex Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fulvestrant · Anastrozole

Start the discussion